https://www.selleckchem.com/products/apx2009.html
1% vs. 46.8%, p0.001), chronic hypertension (38.4% vs. 34.6%, p0.001), in hospital-treated ischaemic heart disease (23.1% vs. 21.5%, p=0.014), and glaucoma (11.1% vs. 6.3%, p0.001) than controls. There was no difference in all-cause mortality between the anti-VEGF treated patients and matched controls (p=0.62). In unadjusted Kaplan-Meier analysis of wet AMD subgroup, all-cause mortality was lower in anti-VEGF treated patients than matched controls (p=0.015), but adjusted Cox´s proportional hazards model showed no difference